Congress Materials – European Lung Cancer Conference (ELCC 2024)
2024 European Lung Cancer Conference | Mar 20-23 | Prague, Czech Republic
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Amivantamab Plus Chemotherapy vs Chemotherapy As First-line Treatment in EGFR Exon 20 Insertion-Mutated Advanced NSCLC: Analysis of Post-Progression Endpoints From PAPILLON
Enriqueta Felip, Catherine Shu, Andres Aguilar, Ke-Jing Tang, Maria Del Rosario Garcia Campelo, Kang-yun Lee, Angelo Delmonte, Joshua K. Sabari, Nicolas Girard, Aaron S. Mansfield, Keunchil Park, Caicun Zhou, Karen Xia, Archan Bhattacharya, Mark Wade, Mahadi Baig, Trishala Agrawal, Parthiv Mahadevia, Roland E. Knoblauch, Rachel E. Sanborn
Amivantamab Plus Chemotherapy vs Chemotherapy in EGFR-Mutant Advanced NSCLC After Progression on Osimertinib: A Post-Progression Analysis of MARIPOSA-2
Ryan D. Gentzler, Alexander I. Spira, Barbara Melosky, Scott Owen, Timothy F. Burns, Erminia Massarelli, Misako Nagasaka, Bruno Fang, Rachel E. Sanborn, Oscar Arrieta, Cynthia Card, Federico Cappuzzo, Karen Xia, Pei-Ling Chu, Sujay Shah, Brooke Diorio, Angela Girvin, Parthiv Mahadevia, Joshua M. Bauml, Karen L. Reckamp
Amivantamab Plus Chemotherapy vs Chemotherapy in EGFR-Mutant Advanced NSCLC After Progression on Osimertinib: Secondary Analyses of Patient-Relevant Endpoints From MARIPOSA-2
Pascale Tomasini, Ana Blasco, Christophe Dooms, Melanie Mackean, Alessandra Bearz, Oscar Juan Vidal, Dariusz Kowalski, Katarzyna Stencel, Raffaele Califano, Pauline Hulo, Veerle Surmont, Alona Zer, Julia Schuchard, Joris Diels, Pei-Ling Chu, Sujay Shah, Brooke Diorio, Angela Girvin, Joshua M. Bauml, Enriqueta Felip
Effect of Amivantamab Dose Interruptions on Efficacy and Safety of First-Line Amivantamab Plus Lazertinib in EGFR-Mutant Advanced NSCLC: Exploratory Analyses from the MARIPOSA study
Maria del Rosario Garcia Campelo, Byoung Chul Cho, Nicolas Girard, Shun Lu, Hiroshige Yoshioka, Jong-Seok Lee, Se-Hoon Lee, Baogang Liu, Mehmet Ali Nahit Sendur, Benjamin Besse, Alexander I. Spira, Enriqueta Felip, Andres Aguilar, Joshua K. Sabari, Sanjay Popat, Parthiv Mahadevia, Seema Sethi, Joshua M. Bauml, Yuriy Ostapenko
Myelosuppression Risk From Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors, Carboplatin Chemotherapy, or Both in EGFR-Mutated Non-small Cell Lung Cancer (NSCLC)
Nicolas Girard, Stephen V. Liu, William William, Kassandra Schaible, Daniela Junqueira, Heather Burnett, Parthiv Mahadevia, Marc Chioda, Joshua M. Bauml, Natasha Leighl
Patient-relevant Endpoints From PAPILLON: Amivantamab Plus Chemotherapy vs Chemotherapy as First-line Treatment of EGFR Exon 20 Insertion-mutated Advanced NSCLC
Luis Paz-Ares, Remi Veillon, Margarita Majem, Caicun Zhou, Ke-Jing Tang, Sang-We Kim, Gary Richardson, Nicolas Girard, Rachel E. Sanborn, Aaron S. Mansfield, Keunchil Park, Jan Sermon, Julia Schuchard, Archan Bhattacharya, Patricia Lorenzini, Mahadi Baig, Trishala Agrawal, Roland E. Knoblauch, Akira Ono, Joshua K. Sabari
Prognostic Factors and Outcomes of Patients With Advanced Non–Small Cell Lung Cancer While on Osimertinib Treatment: A Retrospective Database Study
Maurice Pérol, Christos Chouaid, Andreas Bjerrum, Lise Bosquet, Jedelyn Cabrieto, Irene Luccarini, Nolen Perualila, Joanne Edwards
Subcutaneous Amivantamab Administered Every 4 Weeks (Q4W) in Patients With Advanced Solid Malignancies: The Phase 1b PALOMA Study
Natasha B. Leighl, Anna R. Minchom, Ki Hyeong Lee, Matthew G. Krebs, Byoung Chul Cho, Yu Jung Kim, Melissa L. Johnson, Joshua K. Sabari, Busola Sanusi, Ali Alhadab, Nahor Haddish-Berhane, Donna Zemlickis, Anna Mitselos, Carmel Collins, Mahadi Baig, Joshua M. Bauml, Roland E. Knoblauch, Peter Hellemans, Rachel E. Sanborn
Copies of these presentations are for personal use only and may not be reproduced without written permission of the authors.